The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Douglas G. McNeel, Neil H. Bander, Tomasz (Tom) Beer, Charles G. Drake, Lawrence Fong, Stacey Harrelson, Philip W. Kantoff, Ravi A. Madan, William K. Oh, David J. Peace, Daniel P. Petrylak, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Mark N. Stein, Johannes Vieweg, James L. Gulley

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly.

    Original languageEnglish (US)
    Article number92
    JournalJournal for ImmunoTherapy of Cancer
    Volume4
    Issue number1
    DOIs
    StatePublished - Dec 20 2016

    Fingerprint

    Immunotherapy
    Prostate
    Prostatic Neoplasms
    Carcinoma
    Neoplasms
    Therapeutics
    Clinical Trials
    Second Primary Neoplasms
    Physiologic Monitoring
    Politics
    Dendritic Cells
    Patient Selection
    Cause of Death
    Vaccines
    Nurses
    Physicians

    Keywords

    • Guidelines
    • Immunotherapy
    • Prostate cancer
    • Treatment

    ASJC Scopus subject areas

    • Oncology
    • Immunology and Allergy
    • Cancer Research
    • Molecular Medicine
    • Pharmacology
    • Immunology

    Cite this

    The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. / McNeel, Douglas G.; Bander, Neil H.; Beer, Tomasz (Tom); Drake, Charles G.; Fong, Lawrence; Harrelson, Stacey; Kantoff, Philip W.; Madan, Ravi A.; Oh, William K.; Peace, David J.; Petrylak, Daniel P.; Porterfield, Hank; Sartor, Oliver; Shore, Neal D.; Slovin, Susan F.; Stein, Mark N.; Vieweg, Johannes; Gulley, James L.

    In: Journal for ImmunoTherapy of Cancer, Vol. 4, No. 1, 92, 20.12.2016.

    Research output: Contribution to journalArticle

    McNeel, DG, Bander, NH, Beer, TT, Drake, CG, Fong, L, Harrelson, S, Kantoff, PW, Madan, RA, Oh, WK, Peace, DJ, Petrylak, DP, Porterfield, H, Sartor, O, Shore, ND, Slovin, SF, Stein, MN, Vieweg, J & Gulley, JL 2016, 'The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma', Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 92. https://doi.org/10.1186/s40425-016-0198-x
    McNeel, Douglas G. ; Bander, Neil H. ; Beer, Tomasz (Tom) ; Drake, Charles G. ; Fong, Lawrence ; Harrelson, Stacey ; Kantoff, Philip W. ; Madan, Ravi A. ; Oh, William K. ; Peace, David J. ; Petrylak, Daniel P. ; Porterfield, Hank ; Sartor, Oliver ; Shore, Neal D. ; Slovin, Susan F. ; Stein, Mark N. ; Vieweg, Johannes ; Gulley, James L. / The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. In: Journal for ImmunoTherapy of Cancer. 2016 ; Vol. 4, No. 1.
    @article{f158f86c406e4dd5818c684ec9cc0f0e,
    title = "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma",
    abstract = "Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly.",
    keywords = "Guidelines, Immunotherapy, Prostate cancer, Treatment",
    author = "McNeel, {Douglas G.} and Bander, {Neil H.} and Beer, {Tomasz (Tom)} and Drake, {Charles G.} and Lawrence Fong and Stacey Harrelson and Kantoff, {Philip W.} and Madan, {Ravi A.} and Oh, {William K.} and Peace, {David J.} and Petrylak, {Daniel P.} and Hank Porterfield and Oliver Sartor and Shore, {Neal D.} and Slovin, {Susan F.} and Stein, {Mark N.} and Johannes Vieweg and Gulley, {James L.}",
    year = "2016",
    month = "12",
    day = "20",
    doi = "10.1186/s40425-016-0198-x",
    language = "English (US)",
    volume = "4",
    journal = "Journal for ImmunoTherapy of Cancer",
    issn = "2051-1426",
    publisher = "BioMed Central",
    number = "1",

    }

    TY - JOUR

    T1 - The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

    AU - McNeel, Douglas G.

    AU - Bander, Neil H.

    AU - Beer, Tomasz (Tom)

    AU - Drake, Charles G.

    AU - Fong, Lawrence

    AU - Harrelson, Stacey

    AU - Kantoff, Philip W.

    AU - Madan, Ravi A.

    AU - Oh, William K.

    AU - Peace, David J.

    AU - Petrylak, Daniel P.

    AU - Porterfield, Hank

    AU - Sartor, Oliver

    AU - Shore, Neal D.

    AU - Slovin, Susan F.

    AU - Stein, Mark N.

    AU - Vieweg, Johannes

    AU - Gulley, James L.

    PY - 2016/12/20

    Y1 - 2016/12/20

    N2 - Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly.

    AB - Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly.

    KW - Guidelines

    KW - Immunotherapy

    KW - Prostate cancer

    KW - Treatment

    UR - http://www.scopus.com/inward/record.url?scp=85006741962&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85006741962&partnerID=8YFLogxK

    U2 - 10.1186/s40425-016-0198-x

    DO - 10.1186/s40425-016-0198-x

    M3 - Article

    AN - SCOPUS:85006741962

    VL - 4

    JO - Journal for ImmunoTherapy of Cancer

    JF - Journal for ImmunoTherapy of Cancer

    SN - 2051-1426

    IS - 1

    M1 - 92

    ER -